AstriVax

Ambachtenlaan 1
Heverlee 3001
BE
AstriVax
Foundation date
30/06/2022
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first-in-class Plug & Play vaccine platform with a patented DNA-based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Celyad Oncology appoints Georges Rawadi as its new CEO
Tuesday March 28th 2023
Read more
-
BioLizard appoints Paul Vauterin as Chief Technology Officer
Monday March 27th 2023
Read more
-
ImmuneWatch receives Antwerp Innovation grant to accelerate vaccine development with AI
Monday March 27th 2023
Read more